# Phase 2E independent migration final review

Review coordinate: 2026-07-21 UTC, final saved workspace. The review was filesystem-only; neither Classic nor the renewed database was accessed.

## Verdict

**PASS for Phase 2E specification exit and Phase 2F specification entry only. No importer, persistence, schema change, synchronization runtime, production test or database write is authorized.**

Critical: 0. High: 0. Medium: 0. Low: 0.

The final package contains the required 25 top-level Markdown documents, 19 parseable `2E.1.0` JSON specifications and four Phase 2E evidence manifests. The final focused evidence suites pass: **21 tests, 1,285 assertions** (`Phase2ESpecificationConsistencyTest.php` and `GeneratedEvidenceConsistencyTest.php`).

## Evidence and safety findings closed

- All Classic evidence identities independently reproduce: tool contract, 15 normalized-query hashes, 15 result hashes, aggregate payload and bundle identity. Every published Classic partition balances with difference zero.
- Target implementation, 13 normalized-query hashes, 13 suppression-safe result hashes, content identity and capture-instance identity independently reproduce under the now-explicit canonical preimage contract. Query/result coverage is enforced one-to-one.
- The hash-bound target guard records non-production `uhms_clean`, matching installed-schema fingerprint, session read-only mode, capture time and rollback. All manifest SQL is read-only. This review verified the committed evidence contract and did not independently reconnect to either database.
- `INSURANCE-COMPANY-TO-PROVIDER-PROJECTION-V1` is consistent across the mapping, relationship and provider contracts. Source name/short-name candidates remain diagnostics; provider resolution requires exact canonical `PrivateName`, compatible type and an approved Phase 2A source-row-to-target-provider crosswalk.
- Member-number comparison is exact, case-sensitive and punctuation-preserving. The disjoint reconciliation now separately reports 18 cross-provider/same-patient rows and 16 same-patient/provider rows, avoiding an unsafe same-provider classification.
- The Classic discovery draft now carries the same exact-comparison counts and explicitly prohibits case folding; no superseded member-number diagnostic remains in the package.
- Date/current-state and patient `Company` partitions are precedence-ordered, disjoint and balanced. Unknown dates remain historical-only; reversed/invalid dates fail closed; no status or eligibility is invented.
- Existing-target patients and memberships are immutable. No child enrichment, merge, reassignment, verification event, verifier fallback or operational eligibility call is authorized.
- The unchanged Phase 2C `PATIENT-PRIV-009` token remains the authoritative patient/orphan-chain root. Phase 2E tokens are secondary and domain separated.
- Target nonzero cells below 10 are suppressed; hashes cover only the public suppressed representation. No raw patient/member identifiers, provider names, row tokens, credentials or row-level dates were observed in the Phase 2E artifacts.
- Claims, billing, receivables, payments, accounting, stock and operational side effects remain excluded. Financial reconciliation is therefore not fabricated or silently defaulted in this phase.
- Every JSON specification retains `implementation_authorized=false`, `legacy_uhms`/exact `uuhms` read-only boundaries, authoritative decision references and upstream dependencies. No Phase 2E importer or persistence code was introduced.

## Exit-criterion assessment

The 19 criteria in `PHASE_2E_EXIT_REPORT.md` are supported for a specification-phase exit. In particular, all source fields have one primary disposition; provider, member, chronology, consolidation, provenance, existing-target, eligibility, relationship, exception, reconciliation, extraction and privacy contracts are present and fail closed. The remaining runtime populations and protected crosswalks are honestly labelled Phase 3 dry-run measurements rather than inferred results.

The exit report was correctly gated pending this review; after this verdict the lead recorded the final PASS/Phase 2F specification-only GO. It lists the completed package and specialist/reviewer roles, records the unresolved implementation prerequisites, prohibits persistence and supplies a bounded Phase 2F specification-only prompt. With no findings remaining, Phase 2F specification work may begin.
